Completed PHASE3 INTERVENTIONAL 2-arm NCT01215253

Ranolazine Implantable Cardioverter-Defibrillator Trial (RAID)

Late Sodium Current Blockade in High-Risk ICD Patients

Sponsor: University of Rochester

Conditions Heart Failure Ischemic Cardiomyopathy Nonischemic Cardiomyopathy

Interventions Ranolazine

Updated 10 times since 2017 Last updated: Jul 27, 2018 Started: Sep 30, 2011 Primary completion: Feb 28, 2017 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Heart Failure and Ischemic Cardiomyopathy, this trial is completed. The trial is conducted by University of Rochester and has accumulated 10 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Jul 2018 — Sep 2018 [monthly]

Completed PHASE3
Jun 2018 — Jul 2018 [monthly]

Completed PHASE3
Apr 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Augusta, United States , Austin, United States , Baltimore, United States , Boston, United States , Brandon, United States , Bridgeport, United States , Brooklyn, United States , Burlington, United States , Calgary, Canada and 69 more locations